EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hematological Inflammatory Markers and Chronic Diseases: Current Evidence and Future Perspectives

Monica Dugăeşescu, Iulia Andrei-Bitere, Marina-Raluca Baciu, Eva Dănescu, Alexandru Liţescu, Simina-Teodora Vidroiu, Andrei Manu, Maria Magdalena Constantin, Ioana Roșca, Smaranda Stoleru, Elena Poenaru

Hemato · 27.11.2025 · 6 (4) · 42

DOI: 10.3390/hemato6040042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hemato, online erschienen am 27.11.2025. Verfasst von Monica Dugăeşescu und 10 weiteren Autor:innen. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Complete blood count (CBC)-derived markers such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) have gained increasing attention as accessible indicators of systemic inflammation. These parameters, calculated from routine blood tests, are widely available in clinical settings and are potentially relevant for a variety of chronic diseases. This review aims to explore current evidence and highlight potential future directions regarding the use of hematologic inflammatory biomarkers in chronic disease.

Methods

We performed an extensive literature search on PubMed to identify full-text original studies published in the past five years, focused on investigating the clinical applications of hematologic inflammatory markers in chronic conditions.

Results

CBC-derived inflammatory markers have been studied in a wide range of chronic diseases, including autoimmune diseases, metabolic disorders, chronic kidney disease, chronic infections, psychiatric diseases, and other conditions. These markers have been evaluated for multiple clinical purposes, such as aiding diagnosis, monitoring disease status, assessing disease activity, disease subtype characterization, predicting prognosis, and evaluating associations with disease outcomes.

Conclusions

As chronic diseases affect millions of individuals globally, placing a burden for the healthcare system, patients, and their families, simple and cost-efficient tools like CBC-derived inflammatory markers have the potential to improve clinical case management.

Zitieren

APA

Dugăeşescu, M., Andrei-Bitere, I., Baciu, M., Dănescu, E., Liţescu, A., Vidroiu, S., Manu, A., Constantin, M. M., Roșca, I., Stoleru, S., & Poenaru, E. (2025). Hematological Inflammatory Markers and Chronic Diseases: Current Evidence and Future Perspectives. Hemato, 6(4), 42. https://doi.org/10.3390/hemato6040042

Vancouver

Dugăeşescu M, Andrei-Bitere I, Baciu M, Dănescu E, Liţescu A, Vidroiu S, et al. Hematological Inflammatory Markers and Chronic Diseases: Current Evidence and Future Perspectives. Hemato. 2025;6(4):42. doi:10.3390/hemato6040042

BibTeX
@article{Dugeescu2025,
  author = {Dugăeşescu, Monica and Andrei-Bitere, Iulia and Baciu, Marina-Raluca and Dănescu, Eva and Liţescu, Alexandru and Vidroiu, Simina-Teodora and Manu, Andrei and Constantin, Maria Magdalena and Roșca, Ioana and Stoleru, Smaranda and Poenaru, Elena},
  title = {Hematological Inflammatory Markers and Chronic Diseases: Current Evidence and Future Perspectives},
  journal = {Hemato},
  year = {2025},
  volume = {6},
  number = {4},
  pages = {42},
  doi = {10.3390/hemato6040042}
}
Kostenlos starten →